Refractory autoimmune heparin-induced thrombocytopenia following cardiac surgery

Autoimmune heparin-induced thrombocytopenia (aHIT) is a severe subtype of heparin-induced thrombocytopenia characterized by persistent thrombocytopenia and prothrombotic condition, even though anticoagulation with heparin has been discontinued. Here, we report on a patient with a previous history of aHIT where reexposure to heparin during cardiac surgery resulted in recurrent aHIT with pulmonary embolism. Alternative anticoagulants, as well as high-dose intravenous immunoglobulin, were ineffective, and only multiple cycles of therapeutic plasma exchange restored platelet counts and prevented further thrombosis progression. The therapy was guided by an ex vivo model of antiplatelet factor 4 (PF4)-mediated thrombosis that showed accurate performance in predicting the clinical outcome. Most importantly, the ability to induce thrombus formation was mainly caused by anti-PF4 (heparin-independent) antibodies. Our paper provides the first description of recurrent aHIT with translational evidence that pathogenic heparin-independent anti-PF4 antibodies can be specifically targeted by therapeutic plasma exchange, emphasizing the clinical use in refractory cases of aHIT.

Abstract aus PubMed (NCBI) für den zitierten Eintrag, in der Originalsprache wiedergegeben. Maßgeblich ist die Fassung der Originalpublikation.

Das Abstract wird nicht übersetzt, damit die eigene Wortwahl der Autoren erhalten bleibt.

Case report of recurrent autoimmune HIT with pulmonary embolism after heparin re-exposure during cardiac surgery; alternative anticoagulants and high-dose IV immunoglobulin failed, and repeated therapeutic plasma exchange restored platelet counts and stopped thrombosis progression, guided by an ex vivo anti-PF4 thrombosis model.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Weitere begutachtete Studien in der Kategorie „Arzneimittelentwicklung“.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Draft Genome — Anticoagulant Gene Survey — Kvist S, Manzano-Marín A, de Carle D, Trontelj P, Siddall ME (2020)
• Auswirkungen der Hirudotherapie auf Leberfunktionen, Lipidprofil und Insulinsensitivität bei Ratten mit metabolischem Syndrom — Bilden A et al. (2026)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Medicinal leech therapy (hirudotherapy): a brief overview — Singh A (2010)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Investigation of oxidant-antioxidant status in patients treated with hirudotherapy: an experimental study — Sarikan I, Savas H (2024)
• Leech therapeutic applications — Abdualkader A et al. (2013)
• Non-Occlusive Mesenteric Ischemia Due to Hirudotherapy: A Case Report — Akalın Ç, Ekmen N (2020)
• Leech therapy: a history — Hyson J (2005)

Alle von der ASH analysierten Studien →